FDA inspection
Reese Pharmaceutical Company: FDA inspection ending Nov 24, 2010
FDA inspection 697501 · Official Action Indicated (OAI) · Cleveland, OH
Key facts
| Inspection ID | 697501 |
|---|---|
| Firm | Reese Pharmaceutical Company |
| FEI number | 1518939 |
| Address | 10617 Frank Ave |
| City | Cleveland |
| State | OH |
| ZIP | 44106 |
| Country | United States |
| Fiscal year | 2011 |
| Inspection end date | Nov 24, 2010 |
| Classification | Official Action Indicated (OAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
| Warning letter | 160272 |
At a glance
- 10–99 Citations
- 1–9 Posted citations
- Yes Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data